Precision
About the company
We offer an innovative technology for tumor diagnostics and prediction of treatment effectiveness, based on patient-friendly fine needle biopsies. Precision Biopsies (PB) builds on the latest developments in genetics and protein analysis of tumors and provides more accurate diagnoses and predictions about which therapy to use in individual cases. PB also uses AI-based tools for these purposes. This technology will accelerate tumor diagnostics and improve health economics.
Potential customers include private healthcare providers, pharmaceutical companies, and certain public healthcare institutions. We offer analyses ranging from early diagnostics to longitudinal follow-up, where the use of fine needle biopsy has major advantages due to its non-invasive nature, low risk of complications, and comprehensive information for precision cancer therapy. In addition to its role in direct cancer care and in relation to drug treatment, it provides pharmaceutical companies with the opportunity to evaluate their drugs earlier (providing information on drugs in clinical trials and the frequency of target molecules for drugs in development).
The company is in an early stage with a very high level of scientific excellence from a clinical perspective and significant international market potential. There is a favorable competitive position internationally, where PB is at the forefront of this new technology. In the US, the company Tempus – partially similar profile but is not based on fine needle technology – currently has annual sales of one billion US dollars. The Institute for Health Economics is currently investigating the health economic benefits of our technology.
Quick links:
Contact:
Melissa Florenova, CEO
Email: melissa@florenova.se
Phone: +46 70 779 18 05
Capital need and valuation:
Capital Need: €1,000,000 (first 3 years)
Pre-Money Valuation: Startup
Use of Funds
Primarily product development
Financial forecast
Estimated Turnover 2025/2026: €350,000
Revenue Model: Sales
Previous investments
Founders have invested: €5,000
External investors: €30,000 – grant from Handelsbanken
Additional research funding from Cancerfonden and ThermoFisher Scientific.
Vision and impact
To transform cancer care by delivering innovative, minimally invasive biopsy solutions that combine advanced molecular profiling and AI-driven insights – empowering clinicians to make more accurate treatment decisions (SDG 3 Good Health and well-being).
Risk management
Identified risks: European Health Data Space Regulation (EHDS)
How you manage them: Insights, expertise and partnerships